Sharescart Research Club logo
Products
Research
Tools
About
  • Home
  • /
  • Jagsonpal Pharma
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel

Jagsonpal Pharma

WEBSITE BSE:507789 NSE: JAGSON PHAR Inc. Year: 1978 Industry: Pharmaceuticals & Drugs My Bucket: Add Stock

₹185.4 -6.8 | 3.6%

Last updated: 15:56

Consolidated Standalone

Last updated: 15:56

Jagsonpal Pharma Overview

Jagsonpal Pharmaceuticals Ltd is an primarily India-based pharmaceutical organization engaged in manufacturing of intermediate drugs and pharmaceuticals. The Company focuses on growing and production of bulk capsules and pharmaceutical formulations. It manufactures capsules, pills and ampoules. It operates R&D, manufacturing, marketing and distribution facilities. It develops and manufactures APIs and formulations. It gives products below diverse brands, together with Lycored, which includes lycopene with phytonutrients; Maintane, which include...Read More

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

Jagsonpal Pharma Key Financials

Market Cap ₹1245 Cr.

Stock P/E 22.5

P/B 4.7

Current Price ₹185.4

Book Value ₹ 39.4

Face Value 2

52W High ₹301.8

Dividend Yield 1.35%

52W Low ₹ 154.9

Edit Ratio

Jagsonpal Pharma Share Price

₹ | |

Volume
Price

Jagsonpal Pharma Quarterly Price

Quarterly Monthly
Show Value Show %

Jagsonpal Pharma Peer Comparison

Jagsonpal Pharma Quarterly Results

#(Fig in Cr.) Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Net Sales 58 47 43 61 75 74 59 76 74 73
Other Income 2 3 2 1 2 2 3 3 3 3
Total Income 60 50 46 63 76 76 61 78 77 76
Total Expenditure 49 44 41 51 58 58 50 61 58 57
Operating Profit 11 6 5 12 18 18 11 17 19 19
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 1 2 2 2 2 2 2
Exceptional Income / Expenses 0 0 0 -3 0 23 -0 0 0 -2
Profit Before Tax 10 5 5 7 15 39 9 14 17 15
Provision for Tax 2 1 1 2 4 7 2 4 4 4
Profit After Tax 7 4 4 5 11 32 7 11 13 11
Adjustments 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 7 4 4 5 11 32 7 11 13 11
Adjusted Earnings Per Share 1.1 0.6 0.5 0.8 1.7 1.9 1 1.6 1.9 1.6

Jagsonpal Pharma Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 138 143 144 127 167 159 188 218 237 209 269 282
Other Income 0 1 0 0 1 3 4 3 6 9 8 12
Total Income 138 144 144 127 168 161 192 221 242 218 277 292
Total Expenditure 129 132 138 138 157 150 169 193 203 186 218 226
Operating Profit 9 12 6 -11 11 11 23 28 40 32 59 66
Interest 4 5 3 1 1 1 1 0 0 1 1 0
Depreciation 3 3 2 0 1 1 1 2 1 2 8 8
Exceptional Income / Expenses 0 0 13 0 0 0 0 0 -3 0 20 -2
Profit Before Tax 2 4 14 -12 9 9 22 27 35 30 70 55
Provision for Tax 1 1 3 -0 2 2 5 8 8 7 14 14
Profit After Tax 1 3 12 -12 7 8 17 19 27 22 55 42
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 1 3 12 -12 7 8 17 19 27 22 55 42
Adjusted Earnings Per Share 0.2 0.5 1.8 -1.8 1.1 1.2 2.6 2.9 4.1 3.4 8.3 6.1

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 29% 7% 11% 7%
Operating Profit CAGR 84% 28% 40% 21%
PAT CAGR 150% 43% 47% 49%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -19% 9% 38% 29%
ROE Average 29% 20% 18% 10%
ROCE Average 33% 25% 23% 14%

Jagsonpal Pharma Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 95 98 110 98 104 111 122 133 159 187 240
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 4 4 3 3 3 3 2 4 8 18 26
Total Current Liabilities 55 57 29 29 28 35 40 34 35 19 26
Total Liabilities 154 159 143 130 136 149 164 171 203 225 292
Fixed Assets 52 52 22 21 22 24 26 23 24 9 94
Other Non-Current Assets 6 7 11 14 17 28 18 33 6 19 36
Total Current Assets 96 101 110 95 98 96 120 116 172 180 161
Total Assets 154 159 143 130 136 149 164 171 203 225 292

Jagsonpal Pharma Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 13 15 16 20 15 41 40 59 23 11 13
Cash Flow from Operating Activities 4 9 -3 -2 31 12 28 7 47 35 55
Cash Flow from Investing Activities -0 -2 41 -3 -1 -11 -2 -26 -58 -25 -45
Cash Flow from Financing Activities -1 -6 -34 -1 -6 -2 -7 -18 -0 -9 -12
Net Cash Inflow / Outflow 2 1 5 -6 24 -1 19 -36 -11 2 -2
Closing Cash & Cash Equivalent 15 16 20 15 39 40 59 23 11 13 11

Jagsonpal Pharma Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.18 0.5 1.81 -1.76 1.1 1.2 2.6 2.88 4.08 3.4 8.34
CEPS(Rs) 0.59 0.97 2.12 -1.71 1.26 1.37 2.77 3.11 4.26 3.65 9.56
DPS(Rs) 0.04 0.04 0.04 0.04 0.1 0.2 0.4 1.6 2 2 2.5
Book NAV/Share(Rs) 13.37 13.82 15.59 13.77 14.75 15.76 17.42 20.27 22.92 25.77 32.83
Core EBITDA Margin(%) 6.27 8.19 3.98 -8.77 5.6 2.69 5.08 10.32 13.28 10.28 18.12
EBIT Margin(%) 4.41 6.5 11.75 -8.66 5.84 3.13 5.96 11.11 13.7 13.68 25.13
Pre Tax Margin(%) 1.2 2.83 9.92 -9.18 5.4 2.97 5.82 10.99 13.54 13.31 24.79
PAT Margin (%) 0.84 2.26 8.18 -9.12 4.33 2.48 4.54 7.78 10.39 10.01 19.65
Cash Profit Margin (%) 2.79 4.4 9.55 -8.87 4.93 2.84 4.83 8.41 10.86 10.75 22.53
ROA(%) 0.75 2.08 7.86 -8.48 5.43 5.53 10.9 11.24 14.29 10.52 21.44
ROE(%) 1.35 3.65 12.32 -12.01 7.72 7.88 15.7 15.28 18.89 14.02 28.51
ROCE(%) 4.93 7.32 14.26 -10.52 9.8 9.46 19.43 21.23 24.15 17.72 33.14
Receivable days 118.23 109.58 102.03 93.07 50.22 24.29 16.57 21.26 25.87 25.88 15.63
Inventory Days 83.52 92.27 110.02 142.78 92.03 35.69 28.67 44.76 35.78 29.02 19.56
Payable days 26.19 43.17 49.18 53.98 52.49 76.56 67.24 75.08 69.43 55.17 32.8
PER(x) 63.76 26.36 8.41 0 9.55 5.81 12.22 43.57 28.42 32.94 25.9
Price/Book(x) 0.85 0.95 0.98 0.78 0.71 0.44 1.83 6.19 5.06 4.34 6.58
Dividend Yield(%) 0.35 0.31 0.26 0.37 0.95 2.87 1.26 1.28 1.72 1.79 1.16
EV/Net Sales(x) 0.72 0.76 0.61 0.51 0.2 0.07 0.82 3.66 2.72 2.84 4.86
EV/Core EBITDA(x) 11.2 8.72 14.06 -6.03 3.17 1.05 6.6 27.99 16.17 18.3 22.02
Net Sales Growth(%) -3.96 3.86 0.27 -12.05 31.84 -4.95 18.53 15.77 8.79 -11.83 28.76
EBIT Growth(%) -22.53 52.88 81.83 -164.37 188.87 1.85 125.46 20.29 30.81 -12.89 130.8
PAT Growth(%) -44.78 177.88 264.6 -197.35 162.47 9.07 116.73 10.53 41.72 -15.94 146.45
EPS Growth(%) -44.78 177.91 264.58 -197.35 162.47 9.08 116.72 10.53 41.72 -16.7 145.32
Debt/Equity(x) 0.45 0.43 0.08 0.09 0.04 0.06 0.06 0 0 0 0
Current Ratio(x) 1.74 1.76 3.74 3.31 3.46 2.79 2.98 3.4 4.89 9.39 6.22
Quick Ratio(x) 1.14 1.07 2.12 1.51 2.3 1.94 2.25 2.53 4.31 8.61 5.64
Interest Cover(x) 1.37 1.77 6.44 -16.69 13.08 19.31 43.59 94.48 85.28 37.69 73.92
Total Debt/Mcap(x) 0.53 0.45 0.08 0.12 0.05 0.14 0.03 0 0 0 0

Jagsonpal Pharma Shareholding Pattern

# Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Promoter 68.71 68.48 68.09 68.04 67.97 67.81 67.78 67.65 67.54 67.39
FII 0.38 0.53 0.73 1.1 2.3 2.1 2.1 2.18 2.12 2.12
DII 0.83 0.82 0.85 0.85 0.11 0 0 0.05 0.09 0.15
Public 30.08 30.17 30.33 30.01 29.62 30.08 30.11 30.12 30.25 30.34
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Jagsonpal Pharma News

Jagsonpal Pharma Pros & Cons

Pros

  • Company has delivered good profit growth of 47% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 20%
  • Debtor days have improved from 55.17 to 32.8days.
  • Company is almost debt free.

Cons

  • Stock is trading at 4.7 times its book value.

* The pros and cons are machine generated.

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares
whatsapp

Please Login!

Click to Login
OR
Get free Account

Error!